Alora Pharmaceutical
Alora Pharmaceuticals is a privately held U.S. specialty pharmaceutical holding company operating seven subsidiaries that develop, manufacture, and commercialize branded and generic prescription drugs across seven therapeutic areas—including women's health, endocrinology, and neurology—via a field sales force, U.S. retail/wholesale distribution, and CDMO services.
- Company typePrivate
- Founded2007
- HeadquartersAlpharetta, United States
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Alora Pharmaceutical does
Alora Pharmaceuticals, LLC is a privately held U.S. specialty pharmaceutical holding company headquartered in Alpharetta, Georgia. Founded in 2007, the company operates seven wholly-owned subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop, manufacture, and commercialize branded and generic prescription pharmaceuticals across seven therapeutic areas: women's health, endocrinology, neurology, dermatology, hematology, cough and cold, and pain management. Its branded portfolio includes NP Thyroid (#1 prescribed desiccated thyroid extract in the U.S.), DHIVY (first and only functionally scored carbidopa/levodopa tablet for Parkinson's disease), Relexxii (once-daily methylphenidate for ADHD using the proprietary Osmodex drug delivery platform), and a prenatal vitamin family across multiple sub-brands.
The company's commercial model is anchored by a specialty pharma field sales force engaging prescribers (neurologists, endocrinologists, women's health specialists) combined with U.S. retail/wholesale pharmacy distribution and Group Purchasing Organization contract relationships. Revenue is generated through (1) prescription pharmaceutical sales (branded and generic) across the portfolio, and (2) contract development and manufacturing organization (CDMO) services through Sovereign Pharmaceuticals (Fort Worth, TX) and Osmotica (Marietta, GA), with a combined manufacturing footprint exceeding 300,000 sq. ft. after the January 2022 Monarch PCM acquisition. Distribution is exclusively U.S.-domestic. Growth has been driven by a combination of strategic acquisitions (Sovereign 2019, Osmotica 2021, Monarch 2022), licensing agreements (Cenestin with Aspen Pharma, 2020), and organic new product launches, including FDA approvals and Phase II clinical pipeline progress for the investigational North Star DTE.
Alora Pharmaceutical firmographics
Firmographics- Name
- Alora Pharmaceutical
- Legal name
- Alora Pharmaceuticals, LLC
- Website
- https://alorapharma.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Alora Pharmaceuticals is a privately held U.S. specialty pharmaceutical holding company operating seven subsidiaries that develop, manufacture, and commercialize branded and generic prescription drugs across seven therapeutic areas—including women's health, endocrinology, and neurology—via a field sales force, U.S. retail/wholesale distribution, and CDMO services.
- Ownership category
- akta.pro rank
Alora Pharmaceutical industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Oral Solid Dose (OSD) Generics (HLAIABAD), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Alora Pharmaceutical is headquartered
LocationHeadquarters
- HQ city
- Alpharetta
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Alora Pharmaceutical business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Prescription Pharmaceutical Sales: Revenue generated from sale of branded and generic prescription pharmaceutical products across multiple therapeutic areas including women's health, endocrinology, neurology, dermatology, and pediatrics
- Contract Manufacturing Services: CDMO (Contract Development and Manufacturing Organization) services provided through Sovereign Pharmaceuticals and Osmotica, offering formulation, manufacturing, and packaging capabilities to third-party pharmaceutical companies
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Alora Pharmaceutical product offering
Product offeringCore offering
Alora Pharmaceuticals develops, manufactures, and commercializes branded and generic specialty pharmaceutical products across women's health, endocrinology, neurology, dermatology, hematology, cough & cold, and pain management therapeutic areas. The company operates through seven subsidiaries serving patients with essential medicines while also providing CDMO (contract development and manufacturing organization) services through its Sovereign Pharmaceuticals and Osmotica subsidiaries. The product portfolio spans 90+ products including branded leaders such as NP Thyroid, DHIVY, Relexxii, and Cenestin, manufactured at over 300,000 sq. ft. of US-based facilities.
Product overview
Alora Pharmaceuticals operates as a specialty pharmaceutical company with a multi-brand portfolio structure. The company encompasses seven subsidiaries (Acella, Avion, Neuvosyn, Osmotica, Sovereign, Trigen, and Vertical) that develop and commercialize pharmaceutical products across seven therapeutic areas: Women's Health (prenatal vitamins, contraceptives, menopause support), Endocrinology (hypothyroidism treatments), Neurology (Parkinson's disease, ADHD), Dermatology, Hematology, Cough & Cold, and Pain Management. Key products include NP Thyroid (desiccated thyroid extract for hypothyroidism), DHIVY (carbidopa/levodopa for Parkinson's disease), Relexxii (methylphenidate for ADHD), and various prenatal vitamins. The company also offers contract manufacturing services through Sovereign Pharmaceuticals and controlled drug delivery expertise through Osmotica. Manufacturing facilities are located in Texas and Georgia.
Differentiator
Problem solved
Functional benefit
Products and services
- NP Thyroid Desiccated thyroid extract (DTE) prescription product for treatment of adults with primary hypothyroidism. NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States based on prescriptions filled, serving approximately 1.5 million American hypothyroidism patients who rely on DTE products.
- DHIVY (carbidopa and levodopa) First and only functionally scored carbidopa/levodopa prescription tablet for Parkinson's disease treatment, designed to be divided for precise dosing. Each tablet's four segments contain 6.25/25 mg of CD/LD, enabling neurologists and movement disorder specialists to titrate dosing more precisely than with conventional carbidopa/levodopa tablets.
- Relexxii (methylphenidate hydrochloride extended-release tablets) Once-daily methylphenidate hydrochloride extended-release tablet for treatment of ADHD in adults and pediatric patients 6 years and older. Uses proprietary Osmodex Drug Delivery Technology for controlled release throughout the day. Available in 7 flexible dosing options (18-mg to 72-mg). Relexxii is the largest US manufacturer of methylphenidate medications, addressing ongoing ADHD medication shortages.
- Balcoltra (Low Dose Birth Control) Low-dose oral contraceptive product for women's health, indicated for pregnancy prevention.
- Divigel (Menopause Support) Hormone therapy product for management of moderate to severe menopause symptoms in women.
- Cenestin (synthetic conjugated estrogens, A) Plant-derived mixture of 9 conjugated estrogens indicated for treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg strengths.
- Acella Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Acella brand for women's health, supporting pregnancy and prenatal nutritional needs.
- Avion Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Avion brand for women's health.
- Vertical Rx Prenatal Supplements Prescription prenatal vitamin dietary supplements under the Vertical brand for women's health.
- Bromfed Antihistamine, decongestant, and cough suppressant prescription product for cough & cold symptom relief.
- Prenate Vitamin Family Branded prenatal vitamin product line covering multiple formulations for women's reproductive health and pregnancy support.
- CDMO Services (Sovereign Pharmaceuticals) Contract Development and Manufacturing Organization (CDMO) services offered to third-party pharmaceutical companies, covering formulation, manufacturing, and packaging across solid, semi-solid, and liquid dosage forms with over 300,000 sq. ft. of US-based manufacturing capacity.
- CDMO Services (Osmotica - Controlled Drug Delivery) Contract Development and Manufacturing Organization services specializing in controlled and modified drug delivery systems, offered to third-party pharmaceutical clients leveraging proprietary Osmodex drug delivery technology.
- Hematology Products Pharmaceutical products for hematologic conditions, including treatments under the Avion Pharmaceuticals subsidiary.
- Pain Management Products Pharmaceutical products for pain management, available through Acella Pharmaceuticals and Vertical Pharmaceuticals subsidiaries.
- Dermatology Products Prescription dermatology products available through Acella and Avion Pharmaceuticals subsidiaries.
Quantifiable outcome
- NP Thyroid is the #1 prescribed desiccated thyroid extract in the United States by prescriptions filled
- +2 more outcomes
Companies that use Alora Pharmaceutical
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles2 records
Alora Pharmaceutical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Alora Pharmaceutical partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- MedfindercoreVertical Pharmaceuticals, an Alora company, partnered with Medfinder to help patients prescribed Relexxii (ADHD medication) locate pharmacies with available inventory during ongoing medication shortages. The partnership offers patients Medfinder's AI-enabled pharmacy search service at no cost.
- Paloma HealthcoreAcella Pharmaceuticals partnered with Paloma Health, a virtual medical practice treating hypothyroidism and Hashimoto's disease, to connect patients with NP Thyroid prescription options through Paloma's telehealth platform.
- Aspen Pharma (Aspen Pharmacare Holdings Limited)coreAvion Pharmaceuticals entered a license and commercialization agreement with Aspen Pharma USA Inc. and Aspen Global Incorporated for exclusive rights to relaunch Cenestin (synthetic conjugated estrogens A) tablets in the United States.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Alora Pharmaceutical competitors and assessment
Company assessmentBroad incumbents
- Cambrex: Established small-molecule CDMO offering formulation, manufacturing, and packaging services; relevant benchmark for Alora's Sovereign and Osmotica CDMO business lines.
- Mallinckrodt Pharmaceuticals: Specialty pharmaceutical manufacturer with branded and generic franchises plus in-house CDMO-like operations; broader but comparable in vertical integration and dosage-form breadth.
- Endo Pharmaceuticals: Larger specialty pharma with branded and generic portfolios across women's health, neurology, and pain management; competes across multiple Alora therapeutic areas with broader resources.
Direct peers
- Upsher-Smith Laboratories: Private specialty and generic pharmaceutical company with US manufacturing footprint, focused on niche therapeutic areas and women's health — a closely comparable mid-market specialty pharma.
- Novitium Pharma: Private specialty and generic pharmaceutical CDMO with solid oral dose capabilities; comparable mid-sized US manufacturer serving similar third-party contract manufacturing customers.
- ANI Pharmaceuticals: Specialty generics and branded pharmaceutical manufacturer with similar therapeutic breadth across women's health, neurology, and endocrinology, and a comparable US-focused operating model.
- Padagis: Specialty and generic pharmaceutical company with US manufacturing, distribution, and CDMO capabilities serving similar institutional and retail channels.
- Lannett Company: US-based manufacturer of generic and specialty pharmaceuticals with solid oral dose capabilities; comparable in scale and portfolio mix of branded niche plus high-volume generics.
- Amneal Pharmaceuticals: Vertically integrated generic and specialty pharma with branded, generic, and CDMO offerings across multiple dosage forms; closest large-scale analog to Alora's portfolio and manufacturing strategy.
- Supernus Pharmaceuticals: Specialty pharma with branded CNS products including ADHD and neurology franchises, leveraging proprietary drug delivery technology — analogous to Alora's Osmodex-enabled Relexxii strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Alora Pharmaceutical social profiles
Digital presenceAlora Pharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alora Pharmaceutical leadership team
Management profileNumber of profiles
Profiles10 records
Alora Pharmaceutical subsidiaries and ownership
Company hierarchySubsidiaries8 records
Alora Pharmaceutical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alora Pharmaceutical M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alora Pharmaceutical
What does Alora Pharmaceutical do?
Alora Pharmaceuticals develops, manufactures, and commercializes branded and generic specialty pharmaceutical products across women's health, endocrinology, neurology, dermatology, hematology, cough & cold, and pain management therapeutic areas. The company operates through seven subsidiaries serving patients with essential medicines while also providing CDMO (contract development and manufacturing organization) services through its Sovereign Pharmaceuticals and Osmotica subsidiaries. The product portfolio spans 90+ products including branded leaders such as NP Thyroid, DHIVY, Relexxii, and Cenestin, manufactured at over 300,000 sq. ft. of US-based facilities.
Is Alora Pharmaceutical a public or private company?
Alora Pharmaceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Alora Pharmaceutical founded?
Alora Pharmaceutical was founded in 2007. It employs 501 to 1,000 people.
Where is Alora Pharmaceutical based?
Alora Pharmaceutical is headquartered in Alpharetta, United States, in the North America region.
How does Alora Pharmaceutical make money?
Two revenue lines are on record. Prescription Pharmaceutical Sales are the primary driver. The others are contract Manufacturing Services.
Who are Alora Pharmaceutical's main competitors?
Broad incumbents on record are Cambrex, Mallinckrodt Pharmaceuticals and Endo Pharmaceuticals. Direct peers are Upsher-Smith Laboratories, Novitium Pharma, ANI Pharmaceuticals, Padagis, Lannett Company, Amneal Pharmaceuticals and Supernus Pharmaceuticals.
Does Alora Pharmaceutical have an API?
No public API is recorded for Alora Pharmaceutical.
What industry is Alora Pharmaceutical in?
Alora Pharmaceutical's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 32541 and its SIC code is 2834.